The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - BMSi; Ipsen; Merck; MSD; Pfizer; Roche
Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC).
 
Juliette Logeart
No Relationships to Disclose
 
Audrey Simonaggio
No Relationships to Disclose
 
Reza Thierry Elaidi
No Relationships to Disclose
 
Sophie Hans
No Relationships to Disclose
 
Constance Thibault
Honoraria - Amgen; Astellas Pharma; Janssen-Cilag; Pfizer; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Ipsen; Janssen-Cilag; Pfizer; Sanofi Pasteur
Research Funding - AstraZeneca/MedImmune (Inst); Sanofi Pasteur (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; Janssen-Cilag; Pfizer; Pfizer; Roche/Genentech
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Yann-Alexandre Vano
No Relationships to Disclose